In yesterday’s Wall Street session, Cybin Inc (AMEX:CYBN) shares traded at $0.48, down -5.71% from the previous session.
As of this writing, 5 analysts cover Cybin Inc (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.50, we find $5.00. Given the previous closing price of $0.51, this indicates a potential upside of 880.39 percent. CYBN stock price is now -9.14% away from the 50-day moving average and 19.42% away from the 200-day moving average. The market capitalization of the company currently stands at $196.97M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $5.13 as their price target over the next twelve months.
A total of 26.67% of the company’s stock is owned by insiders.
Wednesday morning saw Cybin Inc (AMEX: CYBN) opened at $0.5200. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.74. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.89, and a quick ratio of 2.89. The fifty day moving average price for CYBN is $0.5272 and a two-hundred day moving average price translates $0.4011 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Sep, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
